vTv Therapeutics wins FDA Breakthrough Therapy designation for type 1 diabetes treatment

A Triad clinical-stage biopharmaceutical company has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration for TTP399 as an adjunctive therapy to insulin for the treatment of type 1 diabetes.   With a company focus on the development of orally administered treatments for type 1 diabetes and psoriasis, High Point-based vTv Therapeutics Inc. (Nasdaq: VTVT) created the treatment as a novel, oral, investigational once-daily glucokinase activator. Breakthrough Therapy…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Source Type: news